Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTX-1088 as Monotherapy and Combined With Pembrolizumab in Advanced Solid Malignancies
NCT05378425Phase 1Active, not recruiting
- Sponsor
- Nectin Therapeutics
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of NTX-1088 in solid tumor (4 arms), sponsored by Nectin Therapeutics. Primary endpoints: Dose-limiting Toxicity at 21 days, Recommended Phase 2 Dose and 1 more. Started Sep 2022; status: active, not recruiting.
02
Drugs
NTX-1088
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05378425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05378425.